Investment Rating - The report does not explicitly provide an investment rating for MGM China [5]. Core Insights - The report aligns with the views of Citic Lyon Research, indicating that MGM International's recent management comments justify the higher licensing and brand fees charged to MGM China, although prior communications could have been handled better [5]. - The market is now focused on whether MGM China will increase its dividend payout ratio to offset the impact of rising costs on profitability, which Citic Lyon believes is a manageable threshold [5][8]. - The significant increase in licensing and brand fee revenue is attributed to MGM China's improved market share and Ebitdar, with total gaming revenue expected to grow 1.7 times to 16.2% and Ebitdar by 1.6 times to $1.203 billion by 2025 [6]. Summary by Sections Licensing Fee Debate - The report discusses the rationale behind MGM International's decision to charge higher fees to MGM China, supported by reverse engineering analysis [5][7]. Dividend Payout Focus - Investors are expected to closely monitor the potential increase in the dividend payout ratio from 50% to above 53% to mitigate the effects of higher fees [8]. Catalysts for Growth - Continuous growth in the mid-market gaming segment, expansion of dividend payout ratios, and supportive Chinese policies are seen as factors driving profit recovery [9]. Company Overview - MGM China operates two casinos in Macau, focusing on high-quality mid-market strategies, with approximately 750 gaming tables, 1,920 slot machines, and 2,003 hotel rooms/suites [11]. Financial Metrics - As of February 9, 2026, MGM China's stock price is HKD 13.14, with a market capitalization of $6.39 billion and a consensus target price of HKD 18.17 [14].

Investment Rating - The report does not explicitly provide an investment rating for Innovent Biologics [4]. Core Insights - Innovent Biologics announced a milestone deal with Eli Lilly on February 8, 2026, granting overseas rights to certain oncology and immunology pipeline assets, receiving an upfront payment of $350 million and potential milestone payments of up to $8.5 billion [4][5]. - This transaction is viewed positively, reinforcing the recognition of Innovent's R&D capabilities by global pharmaceutical companies, which is a significant differentiator in the Chinese biotech sector [6]. - The company is expected to release at least nine Phase I/II data assets in oncology, cardiovascular/metabolic diseases, and autoimmune diseases between 2026 and early 2027, which could unlock substantial option value [6]. Summary by Sections Company Overview - Innovent Biologics is a China-based biopharmaceutical company with a global perspective, focusing on the comprehensive development and commercialization of innovative drugs [10]. Recent Developments - The deal with Eli Lilly involves early development led by Innovent from proof of concept to Phase II, after which Eli Lilly will handle late-stage development and commercialization outside China [5]. - The assets involved in this transaction are undisclosed clinical projects, and the number of projects is fewer than the 11 preclinical assets involved in a previous deal between Hengrui Medicine and GSK [5]. Financial Performance - Innovent's product sales for Q4 2025 reached 3.3 billion yuan, representing a year-on-year growth of over 60%, exceeding market consensus expectations [6]. Catalysts - Key catalysts for 2026 include updates on proof of concept data for IBI363 in frontline non-small cell lung cancer and the initiation of multiple global Phase III projects led by Takeda [7].

中信证券财富管理(香港) 产品及投资方案部 本文是由投资/产品专员而非分析师撰写的文章汇编。 它不构成研究报告，也不应被解释为研究报告，也不旨在提供 专业、投资或任何其他类型的建议或推荐。 CSIWM 个股点评 2026 年 2 月 10 日 星展集团 DBS SP 本文内容由 Kylie Kwok (郭凯欣) 提供 新加坡金融服务行业 电话：(852) 2237 9250 / 电邮：wminvestmentsolutions@citics.com.hk 2025 年四季度业绩：初步观点 摘要 中信证券财富管理与中信里昂研究观点一致。根据中信里昂研究在 2026 年 2 月 9 日发布的题为《4Q25 result: First thoughts》的报告，星展银行（DBS）税后净利润较市场一致预期低 11%。尽管贷款增长强劲，净利息收入基本符合 市场预期。非利息收入低于预期，较市场一致预期低 15%，主因财富管理和交易业务弱于预期。运营成本控制良好。 拨备高于市场预期，因房地产敞口导致特别拨备增加，但一般拨备释放部分抵消了该影响。尽管新增不良资产大幅增 加，不良贷款率保持稳定。季度总股息为 0.81 新加坡元 ...

Market Overview - A-shares opened higher with the Shanghai Composite Index rising 1.41% to 4,123.09 points, and the ChiNext Index up 2.98% to 3,332.77 points, with a total trading volume of approximately 22.7 billion yuan[17] - The Hang Seng Index increased by 1.76% to 27,027.16 points, with major tech stocks rebounding, and total market turnover around 255.1 billion HKD[13] - European markets saw collective gains, with the Euro Stoxx 600 index up 0.7% and the DAX index rising 1.19% to 25,014.87 points, supported by positive economic data[11] Economic Insights - The macroeconomic outlook for Q1 highlights two key points: the impact of the longest Spring Festival holiday on consumption and policy direction from local two sessions[6] - Consumer recovery is characterized by a shift towards service alternatives, while commodity prices remain constrained by household balance sheet recovery[6] - The focus of policy has shifted from traditional infrastructure expansion to granular competition in sectors like low-altitude economy and computing power[6] Commodity and Currency Trends - Oil prices rose for two consecutive days, with NYMEX crude oil up 1.27% to $64.36 per barrel, driven by geopolitical tensions in the Middle East[28] - The dollar index fell by 0.8%, leading to a significant increase in gold prices, which rose 1.3% to $5,050.9 per ounce[28] - The Japanese yen initially fell but later gained 0.9% against the dollar, closing at 155.88[28] Fixed Income Market - U.S. Treasury yields fluctuated, with the 10-year yield at 4.20%, down 0.4 basis points, while the 30-year yield rose by 0.7 basis points to 4.86%[31] - Asian credit markets showed a strong sentiment with overall spreads narrowing by 1-2 basis points, as investors remained cautious ahead of the Lunar New Year[31] Sector Performance - In the U.S., the technology sector led gains, with the Nasdaq up 0.9% and the S&P 500 rising 0.5%[11] - The AI sector showed a 40% quarter-over-quarter growth in annual recurring revenue, indicating a positive trend despite initial skepticism[24] - The white liquor sector is expected to perform better than market expectations during the Spring Festival, driven by strong consumer demand[20]

本文是由投资/产品专员而非分析师撰写的文章汇编。 它不构成研究报告，也不应被解释为研究报告，也不旨在提供 专业、投资或任何其他类型的建议或推荐。 Subaru 7270 JP CSIWM 个股点评 2026 年 2 月 9 日 斯巴鲁的催化因素包括业绩超指引、削减电动车投资细节披露及混合动力车型进入美国市场。 投资风险 斯巴鲁业务面临诸多风险，难以在此详尽列举。主要风险包括汇率波动——由于出口生产与销售货币错配带来的交易 性影响，以及纯折算效应，汇率波动可能抬升或压低利润。此外，公司业绩易受销售市场销量影响，而销量易受消费 者信心、就业、油价、信贷可获得性、利率等宏观经济因素左右。竞争对手定价策略可能影响产品销售利润率。新产 品市场接受度、劳工行动、涉及产品安全的法规诉讼、贸易保护主义法规及环境问题亦构成风险。 日本汽车行业 电话：(852) 2237 9250 / 电邮：wminvestmentsolutions@citics.com.hk 关税与停产 摘要 中信证券财富管理与中信里昂研究观点一致。根据中信里昂研究在 2026 年 2 月 7 日发布的题为《Tariffs and a shutdown》的报 ...

中信证券财富管理(香港) 产品及投资方案部 本文是由投资/产品专员而非分析师撰写的文章汇编。 它不构成研究报告，也不应被解释为研究报告，也不旨在提供 专业、投资或任何其他类型的建议或推荐。 CSIWM 个股点评 Food & Life Companies 3563 JP 日本消费品行业 电话：(852) 2237 9250 / 电邮：wminvestmentsolutions@citics.com.hk 营收基础支撑上行趋势 摘要 中信证券财富管理与中信里昂研究观点一致。根据中信里昂研究在 2026 年 2 月 7 日发布的题为《Revenue foundations fuel upswing》的报告，Food & Life Companies（F&LC）公司的一季度销售额同比增长 24%，营业利润 增长 45%，分别较市场一致预期高出 6%/21%，甚至超越市场最高预期 14%，主要得益于强劲的海外销售及利润率 改善。日本国内同店基础销售额显著增长，预示 2026 年的第二至四季度同店销售额将维持 6-10%的同比增速，足以 抵消大米价格上涨及日本用工成本上升的影响。下一阶段催化因素可能包括中国市场的进一步 ...

Investment Rating - The report maintains a positive outlook on NHPC, aligning with the views of CITIC Lyon Research, indicating confidence in the company's long-term growth potential [5][8]. Core Insights - NHPC's third-quarter performance for FY2026 was impacted by tariff delays and project-related challenges, leading to a nearly 50% decline in net profit due to the lack of tariff approval for the Parbati II project [5][6]. - Despite a 16% year-on-year increase in generation (excluding new projects), NHPC's consolidated net profit declined due to fixed costs and operational challenges [6]. - The report anticipates a turning point in FY2027, with full profit recognition from the Parbati II project expected in the second half of the fiscal year [6]. Summary by Sections Company Overview - NHPC Limited is a mini Ratna I category and 'A' grade central public sector enterprise under the Ministry of Power in India, established in 1975, focusing on the efficient development of hydropower resources [11]. - NHPC operates 22 hydropower stations with a total capacity of 7GW, accounting for 15% of India's total hydropower installed capacity [11]. Project Progress - The Subansiri Lower hydropower project is expected to contribute 46% to NHPC's regulatory equity capital growth from FY2025 to FY2027, with full commissioning anticipated in the third quarter of FY2027 [7]. - The commissioning of the Teesta VI project has been delayed from the third quarter of FY2028 to the second quarter of FY2030 [7]. Growth Prospects - NHPC holds a 15% share of India's hydropower installed capacity and a 50% share in ongoing projects, positioning it for strong profit growth driven by government support for hydropower development and net-zero goals [8]. - The report highlights the potential for significant growth over the next decade, supported by large-scale projects like Parbati II and Subansiri [9].

每周投资策略 产品及投资方案部 ｜2026年2月9日 | | | | | | 环球主要股票市场表现 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 指数 | 收盘价* | 1周变动 | 1个月变动 | 3个月变动 | 1年变动 | 本年变动 | 52周最低 | 52周最高 | 远期红利率 | 远期市盈率 | 远期EPS增长率 | | MSCI ACWI全球指数 | 1,042.82 | (0.1%) | 0.7% | 5.1% | 19.1% | 2.8% | 722.6 | 1,055.0 | 1.8% | 18.6 | 20% | | MSCI WORLD国际资本 | 4,528.99 | 0.0% | 0.5% | 4.7% | 17.2% | 2.2% | 3,155.7 | 4,572.6 | 1.7% | 19.7 | 18% | | MSCI 新兴市场 | 1,506.38 | (1.4%) | 2.7% | 8.1% | 36.7% | 7.3% | 982.6 ...

Investment Rating - The report maintains a positive outlook on KDDI's core business performance, with an expected profit impact of approximately 3% due to ongoing accounting investigations in its advertising subsidiaries [4][7]. Core Insights - KDDI's overall operating profit has shown an 8% year-on-year increase, with a 4% rise in ARPU and stable customer churn rates [4][5]. - The company has announced the establishment of a new AI business integration company named "iret," aiming to increase the number of AI engineers from 1,700 to 3,000 by FY2028 [6]. - The company is facing accounting issues related to its subsidiaries, which are expected to be resolved quickly without significant long-term impacts on cash flow or strategic plans [7]. Summary by Sections Financial Performance - KDDI's revenue increased by 5% year-on-year, with operating profit also up by 8%. The personal business revenue grew by 2%, while the enterprise business revenue rose by 12.5% [5]. - The IoT connections increased by 19% to 66 million, and sales from Starlink/drone services surged by 1.6 times [5]. Mobile Business Developments - The mobile ARPU increased by 4% to 4,550 JPY, with a quarter-on-quarter increase of 2%. The smartphone customer churn rate was 1.23%, slightly up from 1.21% in the previous quarter [6]. - The number of major users remained stable at 42.2 million [6]. Corporate Strategy and Future Outlook - KDDI aims to enhance ARPU revenue through 5G initiatives, targeting over 100 billion JPY profit growth in key areas while reducing costs by approximately 100 billion JPY [11]. - Catalysts for growth include stock buybacks, continued recovery in communication ARPU, and positive results from data center and financial services [8].

本文是由投资/产品专员而非分析师撰写的文章汇编。 它不构成研究报告，也不应被解释为研究报告，也不旨在提供 专业、投资或任何其他类型的建议或推荐。 东京电子 8035 JP 本文内容由 Alex Wu (吴俊豪) 提供 中信证券财富管理(香港) 产品及投资方案部 日本科技行业 电话：(852) 2237 9250 / 电邮：wminvestmentsolutions@citics.com.hk CSIWM 个股点评 2026 年 2 月 9 日 强劲势头 摘要 中 信 证 券 财 富 管 理 与 中 信 里 昂 研 究 观 点 一 致 。 根 据 中 信 里 昂 研 究 在 2026 年 2 月 7 日 发 布 的 题 为 《Strong momentum》的报告，东京电子 2025 年第三季度业绩不及预期，但公司上调 2026 财年指引，预计第四季度将出现 改善。公司同时宣布出售战略持股，并进行最高达 1,500 亿日元的股票回购。管理层预计，2026 年晶圆制造设备 （WFE）市场将实现至少 15%的同比增速，主要由 DRAM 和先进代工/逻辑芯片驱动，而 NAND 和中国市场整体增 长将持平。 第三季度业 ...